There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

The week-ending August 8 saw 20 companies in the healthcare sector report their quarterly earnings. With the earnings season ...

On August 9, Fundstrat’s Tom Lee appeared on CNBC to discuss the current state of the market and the potential for further ...

William “Bill” Joseph Cruser, 80, of Greenwood, IN passed away Tuesday, August 5, 2025, at Community Hospital South in ...

Eli Lilly and Company (NYSE:LLY) is one of the 14 Best Aggressive Growth Stocks to Buy According to Analysts. On July 29, BMO ...

Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly and Company (LLY) is currently at $634.33, down $6.53 or 1.02% --Would be lowest close since Jan. 25, 2024, when it closed at $627.62 --Worst four day stretch since the four days ending Oct.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.